[Association of FGFR2 gene polymorphism with estrogen receptor positive breast cancer detected by fluorescent quantitative PCR]

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Aug;27(4):445-8. doi: 10.3760/cma.j.issn.1003-9406.2010.04.019.
[Article in Chinese]

Abstract

Objective: To investigate the association of fibroblast growth factor receptor 2 gene (FGFR2) rs2981582 polymorphism with breast cancer in Chinese women.

Methods: A case-control study was performed in 936 breast cancer patients and 471 patients with benign breast diseases by using a novel fluorescent quantitative PCR method.

Results: The numbers and frequencies of genotypes CC, CT, and TT in the control group were 234(49.68%), 181(38.43%) and 56(11.89%) respectively. The numbers and frequencies of genotypes CC, CT, and TT in the breast cancer group were 426(44.56%), 400(41.84%) and 130(13.60%) respectively. And no significant difference was found between the two groups (P=0.183). However, stratified analysis found that the numbers and frequencies of genotypes CC, CT, TT in the estrogen receptor(ER) positive subgroup of breast cancer patients were 189(41.27%), 202(46.12%) and 67(14.63%) respectively, and significant difference was observed compared with control group (P=0.035).

Conclusion: Association was found in the single nucleotide polymorphism(SNP) of the rs2981582 locus of intron 2 in FGFR2 gene between the ER positive breast cancer patients and control patients with benign breast diseases. The fluorescent quantitative PCR is a specific, easy-to-operate, low-expense method and is suitable for SNP detection in large scale samples.

Publication types

  • English Abstract

MeSH terms

  • Breast Neoplasms / genetics*
  • Female
  • Genetic Predisposition to Disease*
  • Humans
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Single Nucleotide / genetics*
  • Receptor, Fibroblast Growth Factor, Type 2 / genetics*
  • Receptors, Estrogen / genetics*

Substances

  • Receptors, Estrogen
  • Receptor, Fibroblast Growth Factor, Type 2